Search
Tractament de la psoriasi en plaques: informe d'avaluació de resultats
(2022)
This report selected the data of patients with moderate to severe plaque psoriasis treated with adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, tildrakizumab, ...
Adalimumab, golimumab, infliximab, vedolizumab i tofacitinib per al tractament de la colitis ulcerosa en pacients adults
(2019-12-19)
Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease (IBD) that affects the rectum and colon with varying degrees of extent and severity (proctitis, left or distal colitis, and extensive colitis or ...
Dupilumab per al tractament de la dermatitis atòpica en adults candidats a tractament sistèmic
(2020-03-10)
Atopic dermatitis (AD) is an inflammatory, chronic or chronically recurrent and non-contagious skin disease that frequently affects patients with a personal or family history of atopic diseases (asthma, allergic ...
Tractament i profilaxi postexposició de la infecció pel virus de la immunodeficiència humana de tipus 1 (VIH-1): informe d'avaluació de resultats
(2021)
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus with a high capacity for replication and mutation that especially infects CD4 T lymphocytes, and causes quantitative and qualitative immunodeficiency of these ...
Alectinib, ceritinib, crizotinib i brigatinib per al tractament del càncer de pulmó no microcític localment avançat o metastàsic, posiyiu per la cinasa del limfoma anaplàstic (ALK)
(2019-03-04)
Lung cancer is the leading cause of cancer-related mortality around the world. The 2018 global estimates of the incidence of cancer and mortality for GLOBOCAN indicate a total of 2 million new cases and 1.7 million deaths ...
Tafamidís, inotersèn i patisiran per al tractament de l'amiloïdosi transtiretina hereditària
(2020-06-16)
Transstyretin amyloidosis (ATTR) is a minor, progressive, and deadly disease caused by extracellular deposits of amyloid fibers composed of transthyretin (TTR) in various organs. Under normal conditions, TTR is a protein ...
Informe d'utilització de sacubitril/valsartan a Catalunya: informe d'utilització de medicaments
(2020)
SAC / VAL is considered a treatment option for patients with heart failure with reduced ejection fraction (≤ 35%), high levels of type B natriuretic peptide (PNB) or aminothermal fragment of type B natriutetic peptide ...